Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
Open Access
- 1 April 2006
- journal article
- review article
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 19 (2), 435-47
- https://doi.org/10.1128/cmr.19.2.435-447.2006
Abstract
Developing interpretive breakpoints for any given organism-drug combination requires integration of the MIC distribution, pharmacokinetic and pharmacodynamic parameters, and the relationship between in vitro activity and outcome from both in vivo and clinical studies. Previously, the Subcommittee for Antifungal Testing of the Clinical and Laboratory Standards Institute (CLSI [formerly National Committee for Clinical Laboratory Standards]) proposed MIC interpretive breakpoints for fluconazole and Candida spp. These breakpoints were considered to be somewhat weak, because the clinical data supporting them came largely from mucosal infections and there were very few infections involving strains with elevated fluconazole MICs. We readdress the issue of fluconazole breakpoints for Candida by using published clinical and microbiologic data to provide further validation of the breakpoints proposed by the CLSI in 1997. We also address interpretive breakpoints for agar disk diffusion testing of fluconazole. The MIC distribution for fluconazole was determined with a collection of 13,338 clinical isolates. The overall MIC at which 90% of the isolates were inhibited was 8 microg/ml: 91% were susceptible (S) at a MIC of or= 64 microg/ml). Similar results were obtained for 2,190 isolates from randomized clinical trials. Analysis of available data for 1,295 patient-episode-isolate events (692 represented mucosal infections and 603 represented invasive infections) from 12 published clinical studies demonstrated an overall success rate of 77%, including 85% for those episodes in which the fluconazole MIC was or= 64 microg/ml) isolates. Pharmacodynamic analysis demonstrated a strong relationship between MIC, fluconazole dose, and outcome. A dose/MIC ratio of approximately 25 was supportive of the following susceptibility breakpoints for fluconazole and Candida spp.: S, MIC or= 64 microg/ml. The corresponding disk test breakpoints are as follows: S, >or=19 mm; SDD, 15 to 18 mm; R, <or=14 mm.Keywords
This publication has 118 references indexed in Scilit:
- International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemiaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemiaDiagnostic Microbiology and Infectious Disease, 2004
- Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- The role of antifungal susceptibility testing in the therapy of candidiasisDiagnostic Microbiology and Infectious Disease, 2004
- In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance programDiagnostic Microbiology and Infectious Disease, 2004
- Voriconazole Salvage Treatment of Invasive CandidiasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for DeathEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazoleDiagnostic Microbiology and Infectious Disease, 2002
- Precision and Accuracy of Fluconazole Susceptibility Testing by Broth Microdilution, Etest, and Disk Diffusion MethodsAntimicrobial Agents and Chemotherapy, 2002
- FluconazoleDrugs, 1990